Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry ...

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for ...

Laekna (2105.HK) today announced that the company will present an internally discovered preclinical candidate at the 2024 San Antonio Breast Cancer Symposium (SABCS) on December 13, 2024. The ...

TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. SitesTUS and TUS+VEN Broadly ...

Designing a killer poster on a budget is like finding the last slice of pizza at a party—totally doable if you’re smart about ...

In contrast to an oral presentation, a “poster” is a visual representation of the research project that must convey the essence of your message. In effect, it “talks” for the researcher. The poster ...

Pharma Two B announced a poster presentation of integrated safety and efficacy data on P2B001 from its Phase 2b and Phase 3 studies in ...

LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, Dec. 4, 2024 /PRNewswire/ -- Flamingo Therapeutics ("Flamingo") today announced that an abstract has been selected for presentation at the 66th ...

The Versailles FFA Safety Committee sponsored a Safety Poster Contest and presented a safety presentation about home, farm ...

The abstract, selected for a poster presentation, is a Trials-in-Progress presentation of a Phase 1 investigator-initiated study of danvatirsen monotherapy followed by danvatirsen combination ...

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ...

(TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response targeting technologies, is pleased to announce an ...